Edwards Lifesciences
Global specialist in the science of heart values and hemodynamic monitoring.
Launch date
Employees
Market cap
$41.0b
Enterprise valuation
$39.7b (Public information from Sep 2024)
Share price
$66.83 EW
Irvine California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 4.4b | 5.2b | 5.4b | 6.0b | 6.5b | 7.0b | 7.7b |
% growth | 1 % | 19 % | 3 % | 12 % | 8 % | 9 % | 9 % |
EBITDA | 1.7b | 1.5b | 1.8b | 1.9b | 2.0b | 2.2b | 2.5b |
% EBITDA margin | 40 % | 28 % | 34 % | 32 % | 31 % | 32 % | 32 % |
Profit | 823m | 1.5b | 1.5b | 1.4b | 1.5b | 1.8b | 2.0b |
% profit margin | 19 % | 29 % | 28 % | 23 % | 24 % | 25 % | 25 % |
EV / revenue | 12.8x | 15.4x | 8.5x | 7.5x | 6.3x | 5.6x | 5.1x |
EV / EBITDA | 32.4x | 54.4x | 25.1x | 23.2x | 20.1x | 17.7x | 15.7x |
R&D budget | 761m | 903m | 945m | 1.1b | - | - | - |
R&D % of revenue | 17 % | 17 % | 18 % | 18 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | N/A | IPO | |
Total Funding | - |
Recent News about Edwards Lifesciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Edwards Lifesciences
EditACQUISITION by Edwards Lifesciences Oct 2012
ACQUISITION by Edwards Lifesciences Nov 2016
BUYOUT by BC Partners Jul 2021
ACQUISITION by Edwards Lifesciences Jul 2024
ACQUISITION by Edwards Lifesciences Mar 2011
ACQUISITION by Edwards Lifesciences Jul 2015
ACQUISITION by Edwards Lifesciences Jul 2024
ACQUISITION by Symetis Feb 2017
ACQUISITION by Johnson & Johnson Aug 2024